问荆碱对大鼠脑囊泡膜Mg2+-ATPase,Ca2+-ATPase抑制作用的动力学研究

问荆碱对大鼠脑囊泡膜Mg²⁺-ATPase,Ca²⁺-ATPase有显著的抑制作用,对Mg²⁺-ATPase的抑制机制分别为竞争性抑制(Mg²⁺,Ki=4.93×10^-5mol/L)、非竞争性抑制(ATP,Ki=1.06×10^-4mol/L),对Ca²⁺-ATPase的抑制机制分别为混合型抑制(Ca²⁺,Ki=5.07×10^-5mol/L)、非竞争性抑制(ATP,Ki=3.27×10-4mol/L)。     

抗角蛋白自身抗体对豚鼠银屑病样皮炎的影响

目的 观察豚鼠抗角蛋白自身抗体（anti-keratin au-toantibody,AK auto Ab）滴度的消长对豚鼠银屑病样皮炎转归的作用。方法 应用心得安乳剂涂抹豚鼠耳廓造成银屑病样皮炎，采用腹腔注射纯化的豚鼠AK auto Ab（高滴度组）、皮下植入自身皮片消耗AK auto Ab（低滴度组）以及不作处理（正常滴度组）作为对照，根据组织病理变化评价豚鼠血清AK auto Ab滴度消长对皮炎转归的影响。结果 AK atuo Ab高滴度组银屑病样皮炎的恢复速度明显于对照组，而低滴度组皮炎恢复最缓慢。结论 AK auto Ab具有促进豚鼠银屑病样皮炎恢复的作用。     

国内信息行为研究的主题和科研合作分析

【目的】通过对国内现有的信息行为研究文献的分析,揭示国内信息行为研究领域科学研究主题的结构情况。【方法】因子分析法和共词聚类分析法。为了能够科学地对国内信息行为研究主题分析,本文运用因子分析和共词聚类方法对国内信息行为的研究文献中关键词进行分析及聚类,并探讨该领域研究主题的结构。【结果】发现目前国内信息行为研究主题集中在信息素养、网络信息行为、信息行为模型、信息传播、图书馆信息服务等12个方面。【结论】国内信息行为热点研究存在着研究对象多样化、研究主题分散化、研究热度均衡化等特征。     

补体C3基因敲除小鼠基因型鉴定的PCR条件优化

目的对补体C3基因敲除小鼠基因型鉴定的PCR反应体系及扩增程序进行优化,检测PCR优化体系的适用性和灵敏性。方法通过改进引物设计、改变PCR反应过程中Mg2＋浓度、引物浓度、退火温度、模板DNA浓度及反应循环次数,分析比较PCR扩增效果。结果优化后的补体C3基因敲除小鼠基因型鉴定的PCR反应体系中,Mg2＋浓度在2-4mmol/L,引物浓度在0.025-0.4μmol/L,循环次数在30-45次之间均能扩增得到清晰均一的特异性条带;同时,引物退火温度在55.5℃-69.6℃范围内均适用;优化后PCR体系能够检测的最低DNA浓度为1.41ng/μl,即模板DNA在反应体系中的总量为约2.82ng.结论已经建立的优化后的PCR基因扩增体系特异性高且稳定可靠。     

Nanocomposites based on the graphene family for food packaging: historical perspective,preparation methods,and properties

Nanotechnology experienced a great technological advance after the discovery of the graphene family (graphene – Gr, graphene oxide – GO, and reduced graphene oxide-rGO). Based on the excellent properties of these materials, it is possible to develop novel polymeric nanocomposites for several applications in our daily routine. One of the most prominent applications is for food packaging, offering nanocomposites with improved thermal, mechanical, anti-microbial, and barrier properties against gas and water vapor. This paper reviewed food packaging from its inception to the present day, with the development of more resistant and intelligent packaging. Herein, the most common combinations of polymeric matrices (derived from non-renewable and renewable sources) with Gr, GO, and rGO and their typical preparation methods are presented. Besides, the interactions present in these nanocomposites will be discussed in detail, and their final properties will be thoroughly analyzed as a function of the preparation technique and graphene family-matrix combinations.

Food packaging based on nanotechnology of polymeric nanocomposites of graphene and graphene oxide results in packaging with better thermal, mechanical, antimicrobial, electrical packaging, moisture barrier and gas properties.     

葫芦素E抑制多发性骨髓瘤细胞增殖及与阿霉素的协同效应?

目的：研究葫芦素 E 对人多发性骨髓瘤细胞增殖和凋亡的影响,并观察葫芦素 E 与阿霉素的协同效应。方法采用 CCK-8测定葫芦素 E 对4种多发性骨髓瘤细胞 MM1.S、MM1.R、U266和 RPMI8226的半数生长抑制率(GI50),并通过 CalcuSyn 协同效应分析软件,计算药物合用指数(CI),评价葫芦素 E 与阿霉素协同抗多发性骨髓瘤作用;流式细胞术检测葫芦素 E 对 MM1.S、MM1.R 的细胞周期、线粒体膜电位和细胞凋亡的影响;Western blot 检测凋亡相关蛋白 Caspase-3和 PARP 的变化,以及葫芦素 E 对 IL-10刺激的 RPMI8226细胞STAT3蛋白磷酸化的抑制作用。结果葫芦素 E 对4种多发性骨髓瘤细胞的 GI50均在(12.3~161.7)nM 范围内;葫芦素 E 导致多发性骨髓瘤细胞的 SubG1期细胞比例、凋亡细胞比例和线粒体膜电位下降细胞比例均明显增加,并出现凋亡相关的活化蛋白如 Cleaved Caspase-3和 Cleaved-PARP。葫芦素 E 能有效抑制 IL-10诱导的RPMI8226细胞 STAT3磷酸化,并能与阿霉素协同抗多发性骨髓瘤。结论葫芦素 E 通过抑制 STAT3蛋白磷酸化,诱导多发性骨髓瘤细胞凋亡,并能协同阿霉素抗多发性骨髓瘤。     

高风险患者腹主动脉瘤手术与腔内治疗效果的比较

目的 比较高风险患者腹主动脉瘤(abdominal aortic aneurysm,AAA)手术治疗(opensurgical repair,OSR)与腔内治疗(endovascular aneurysm repair,EVAR)的效果,探讨高风险患者AAA治疗方式的选择.方法 利用(customized probability index,CPI)危险评分方法[1]筛选出我院1998年至2008年高风险患者55例,比较OSR组(20例)与EVAR组(35例)围手术期及术后近期结果.结果 OSR组随访率100%,平均随访6年3个月.EVAR组随访率94%,平均随访5年10个月.(1)手术时间高风险患者EVAR组(3.1±0.6)h短于OSR组[(4.9±0.9)h(P<0.05)];(2)EVAR组术中出血、ICU时间和住院时间均短于OSR组(P<0.01);(3)围手术期死亡率EVAR组(2.86%)明显低于OSR组(15.00%);(4)术后并发症发生率EVAR组(17%)明显低于OSR组(40%);(5)EVAR组术后并发症主要为内漏(8.57%);(6)OSR组并发症主要为心脏相关性疾病(25%).结论 EVAR对于高风险患者AAA的治疗可以更少的导致围手术期心血管事件的发生,降低围手术期的死亡率和并发症发生率.CPI可以相对准确评估血管手术围手术期死亡率和并发症的发生率,可用于指导围手术期的治疗策略.     

Combination effect of ribavirin and erythropoietin treatment on hemoglobin A1c in a diabetic patient with chronic hepatitis C

Any condition that shortens erythrocyte lifespan or decreases mean erythrocyte age may falsely lower hemoglobin A1c (A1C) test results. Ribavirin (RBV) used for chronic hepatitis C virus (HCV) infection can cause reversible hemolytic anemia; erythropoietin (EPO) used for treatment-related anemia can stimulate the production of red blood cells. We reported a 55-year-old woman with diabetes who received peginterferon alfa plus RBV for HCV infection. Four weeks following HCV therapy, her Hb level declined from 13.3 g/dL to 11.3 g/dL with elevated lactate dehydrogenase and reduced haptoglobin, which confirmed hemolysis. As her Hb fell to a nadir of 8.5 g/dL at the eighth week, darbepoetin alfa was administered to treat anemia consecutively for 10 weeks. Two months later, the patient's A1C declined from 7.5% to an extremely low value of 4.0%, accompanied by a fasting glucose level of 116 mg/dL. During the preceding 3 months, there was no self-reported hypoglycemia or documented low blood glucose. About 3 months after HCV therapy was terminated, the A1C returned to 6.1% without medication adjustment. The concurrent use of RBV and EPO treatments can synergistically cause falsely low A1C values and may lead to inappropriate relaxation of glycemic control. During HCV treatment with RBV, A1C should not be used alone to guide diabetes therapy.